Brief: Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
16/05/2024 13:41
May 16 (Reuters) - Avenue Therapeutics Inc ATXI.O :
* AVENUE THERAPEUTICS INC - ANNOUNCED COMPLETION OF LAST
PATIENT'S
FINAL VISIT IN COMPANY'S PHASE 1B/2A CLINICAL TRIAL OF AJ201
* AVENUE THERAPEUTICS INC - TOPLINE DATA ARE EXPECTED TO BE
REPORTED MID-YEAR 2024
Source text for Eikon: ID:nGNX8t6mjd
Further company coverage: ATXI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fortress Biotech
See all newsFortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi